Q32 Bio (QTTB) to Release Quarterly Earnings on Tuesday

Q32 Bio (NASDAQ:QTTB) is expected to be releasing its earnings data before the market opens on Tuesday, March 11th. Analysts expect Q32 Bio to post earnings of ($1.25) per share for the quarter.

Q32 Bio Stock Down 4.8 %

QTTB stock opened at $2.16 on Tuesday. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.61. The business has a 50 day moving average price of $3.07 and a two-hundred day moving average price of $25.14. The company has a market cap of $26.31 million, a price-to-earnings ratio of -0.15 and a beta of -0.32. Q32 Bio has a twelve month low of $2.13 and a twelve month high of $53.79.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on QTTB. Leerink Partnrs cut Q32 Bio from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Guggenheim cut Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Leerink Partners reaffirmed a “market perform” rating and issued a $9.00 price objective (down from $68.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Piper Sandler cut Q32 Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $20.00 to $4.00 in a research report on Tuesday, February 11th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $22.00 price objective (down from $90.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $24.86.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.